Eli Lilly And Company ( (LLY) ) has released its Q1 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its investors.
Eli Lilly and Company is a global pharmaceutical company known for its innovative research and development in the healthcare sector, focusing on areas such as diabetes, oncology, and immunology.
In the first quarter of 2025, Eli Lilly reported a significant 45% increase in revenue, reaching $12.73 billion, driven by strong sales of key products like Mounjaro and Zepbound. The company also highlighted progress in its pipeline, including positive Phase 3 trial results for orforglipron, an oral GLP-1 agonist for Type 2 diabetes.
Key financial metrics for the quarter included a 23% increase in reported earnings per share (EPS) to $3.06 and a 29% increase in non-GAAP EPS to $3.34. The gross margin rose by 48% to $10.50 billion, reflecting improved production costs and a favorable product mix. The company also reaffirmed its revenue guidance for 2025, projecting between $58.0 billion and $61.0 billion.
In addition to financial performance, Eli Lilly announced strategic initiatives such as accelerating manufacturing investments and expanding its product offerings, including new doses for Zepbound. The company also received regulatory approvals in oncology and immunology, further strengthening its market position.
Looking ahead, Eli Lilly remains optimistic about its growth prospects, with management reaffirming revenue guidance and continuing to invest in its pipeline and manufacturing capabilities to meet global demand for its innovative medicines.